Comparisons of survival outcomes between bevacizumab and olaparib in BRCA-mutated, platinum-sensitive relapsed ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3052)

OBJECTIVE: To compare survival outcomes between bevacizumab (BEV) and olaparib (OLA) maintenance therapy in BRCA-mutated, platinum-sensitive relapsed (PSR) high-grade serous ovarian carcinoma (HGSOC). METHODS: From 10 institutions, we identified HGSOC patients with germline and/or somatic BRCA1/2 mu...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Se Ik, Lee, Jeong-Won, Kim, Kidong, Lee, Maria, Yoo, Jigeun, Choi, Min Chul, Hwangbo, Suhyun, Kwak, Young Hwa, Lee, Jong-Min, Shin, So-Jin, Shim, Seung-Hyuk, Kim, Min Kyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8550925/
https://www.ncbi.nlm.nih.gov/pubmed/34431258
http://dx.doi.org/10.3802/jgo.2021.32.e90

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8550925/
https://www.ncbi.nlm.nih.gov/pubmed/34431258
http://dx.doi.org/10.3802/jgo.2021.32.e90

Ejemplares similares